SSA
TSHA icon

Schonfeld Strategic Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-843,200
Closed -$1.69M – 2391
2024
Q3 		$1.69M Buy
843,200
+74,000
+10% +$162K 0.01% 955
2024
Q2 		$1.72M Buy
769,200
+216,605
+39% +$630K 0.01% 973
2024
Q1 		$1.59M Sell
552,595
-566,780
-51% -$1.18M 0.01% 1064
2023
Q4 		$1.98M Buy
1,119,375
+399,332
+55% +$796K 0.01% 801
2023
Q3 		$2.28M Buy
+720,043
New +$1.34M 0.02% 794
2022
Q4 		– Sell
-11,000
Closed -$22K – 3017
2022
Q3 		$22K Sell
11,000
-13,100
-54% -$47.6K ﹤0.01% 2709
2022
Q2 		$90K Buy
24,100
+4,100
+21% +$16.3K ﹤0.01% 2164
2022
Q1 		$131K Buy
+20,000
New +$150K ﹤0.01% 2156

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's TSHA Position: Q4 2024 in Review

Schonfeld Strategic Advisors sold out of Taysha Gene Therapies (TSHA) in Q4 2024, closing a stake of 843,200 shares — an estimated $1.69M sold.

Schonfeld Strategic Advisors first reported a position in TSHA in Q1 2022 and held it in 8 quarters. The position peaked at $2.28M in Q3 2023. 131 funds tracked by Wall St. Rank hold TSHA as of Q4 2024.

  • Schonfeld Strategic Advisors reported no remaining Taysha Gene Therapies position as of Q4 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 843,200 Taysha Gene Therapies shares in Q4 2024, an estimated $1.69M.
  • Schonfeld Strategic Advisors first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's Taysha Gene Therapies position peaked at $2.28M in Q3 2023.
  • 131 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.